Advances in Tumour Biomarkers for Screening, Diagnosis and Management of Ovarian Malignancies
Ovarian cancer is one of most deadly malignancies in women, accounting for 1,52,000 deaths annually worldwide. Most ovarian malignancies are diagnosed at advanced stages when they have already metastasised to distant sites. Many researches are still under way to find means of detecting this malignan...
Main Authors: | , |
---|---|
Format: | Article |
Language: | English |
Published: |
JCDR Research and Publications Private Limited
2018-04-01
|
Series: | Journal of Clinical and Diagnostic Research |
Subjects: | |
Online Access: | https://jcdr.net/articles/PDF/11453/34896_CE(RA1)_F(AP)_PF1(MLS_BT_SHU)_PFA(NC_BT_SL)_PB(BT_SL)_PN(SL).pdf |
id |
doaj-3078a9c62d014aa9b757af728d6fdd0d |
---|---|
record_format |
Article |
spelling |
doaj-3078a9c62d014aa9b757af728d6fdd0d2020-11-25T02:10:47ZengJCDR Research and Publications Private LimitedJournal of Clinical and Diagnostic Research2249-782X0973-709X2018-04-01124QE01QE0710.7860/JCDR/2018/34896.11453Advances in Tumour Biomarkers for Screening, Diagnosis and Management of Ovarian MalignanciesNaina Kumar0Amit Kant Singh1Associate Professor, Department of Obstetrics and Gynaecology, Maharishi Markandeshwar Institute of Medical Sciences and Research, Ambala, Haryana, India.Professor, Department of Physiology, Uttar Pradesh University of Medical Sciences, Saifai, Etawah, Uttar Pradesh, India.Ovarian cancer is one of most deadly malignancies in women, accounting for 1,52,000 deaths annually worldwide. Most ovarian malignancies are diagnosed at advanced stages when they have already metastasised to distant sites. Many researches are still under way to find means of detecting this malignancy at an early stage, so as to improve overall survival rates associated with it. One such way is use of serum biomarkers, which can help to some extent in detecting these cancers at an early stage as well as to follow-up patients during chemotherapy, after surgery and for detection of recurrent/persistent disease. Present review throws light on some of these novel biomarkers that help in detection and follow-up of women with ovarian cancers. https://jcdr.net/articles/PDF/11453/34896_CE(RA1)_F(AP)_PF1(MLS_BT_SHU)_PFA(NC_BT_SL)_PB(BT_SL)_PN(SL).pdfantibodiescancerchemotherapy |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Naina Kumar Amit Kant Singh |
spellingShingle |
Naina Kumar Amit Kant Singh Advances in Tumour Biomarkers for Screening, Diagnosis and Management of Ovarian Malignancies Journal of Clinical and Diagnostic Research antibodies cancer chemotherapy |
author_facet |
Naina Kumar Amit Kant Singh |
author_sort |
Naina Kumar |
title |
Advances in Tumour Biomarkers for Screening, Diagnosis and Management of Ovarian Malignancies |
title_short |
Advances in Tumour Biomarkers for Screening, Diagnosis and Management of Ovarian Malignancies |
title_full |
Advances in Tumour Biomarkers for Screening, Diagnosis and Management of Ovarian Malignancies |
title_fullStr |
Advances in Tumour Biomarkers for Screening, Diagnosis and Management of Ovarian Malignancies |
title_full_unstemmed |
Advances in Tumour Biomarkers for Screening, Diagnosis and Management of Ovarian Malignancies |
title_sort |
advances in tumour biomarkers for screening, diagnosis and management of ovarian malignancies |
publisher |
JCDR Research and Publications Private Limited |
series |
Journal of Clinical and Diagnostic Research |
issn |
2249-782X 0973-709X |
publishDate |
2018-04-01 |
description |
Ovarian cancer is one of most deadly malignancies in women, accounting for 1,52,000 deaths annually worldwide. Most ovarian malignancies are diagnosed at advanced stages when they have already metastasised to distant sites. Many researches are still under way to find means of detecting this malignancy at an early stage, so as to improve overall survival rates associated with it. One such way is use of serum biomarkers, which can help to some extent in detecting these cancers at an early stage as well as to follow-up patients during chemotherapy, after surgery and for detection of recurrent/persistent disease. Present review throws light on some of these novel biomarkers that help in detection and follow-up of women with ovarian cancers. |
topic |
antibodies cancer chemotherapy |
url |
https://jcdr.net/articles/PDF/11453/34896_CE(RA1)_F(AP)_PF1(MLS_BT_SHU)_PFA(NC_BT_SL)_PB(BT_SL)_PN(SL).pdf |
work_keys_str_mv |
AT nainakumar advancesintumourbiomarkersforscreeningdiagnosisandmanagementofovarianmalignancies AT amitkantsingh advancesintumourbiomarkersforscreeningdiagnosisandmanagementofovarianmalignancies |
_version_ |
1724917456199221248 |